



USNRC/Office of Nuclear Regulatory Research
Health Physics “Brownbag” Lunch Meeting
NRC HQ White Flint North Building
Wednesday April 14th, 11:30 am – 1:00 pm

The IMBA Expert™/Professional Plus Approach to Implementing ICRP Recommendations for Internal Dose Assessment: Adaptation for U.S. Regulatory Requirements

by

Anthony C. James, PhD, CRadP
USTUR Director

Research Professor, College of Pharmacy
Washington State University

tjames@tricity.wsu.edu
www.ustur.wsu.edu



***“Learning from Plutonium
and Uranium Workers”***

What Is “IMBA”?

- The acronym “**IMBA**” stands for **I**ntegrated **M**odules for **B**ioassay **A**nalysis.
- During 1997-1999, the UK National Radiological Protection Board (NRPB), in collaboration with British Nuclear Fuels plc (BNFL) and Westlakes Research Institute developed **IMBA**:
 - a suite of software modules that implement the current, i.e., ICRP Publication 68 (1994), models for estimation of intakes and doses.
- The resulting product, NRPB’s “**IMBA modules**,” went through extensive (well documented) quality assurance, and:
 - By 2000 were adopted for routine formal dose assessment by Approved Dosimetry Services (ADS) throughout the UK.

Why Was IMBA Necessary?

- The increased complexity of models representing the biokinetic behavior of radionuclides in the body following intake, that were introduced in ICRP Publication 68, posed major problems for people who were required to implement these models, e.g., UK Approved Dosimetry Services (ADS).
- Prior to ICRP 68, in common with international (and U.S.) practice, UK ADSs were set up to use the ICRP Publication 26 methodology (ICRP, 1977) for calculating doses together with empirically-based **metabolic** models from ICRP Publication 30 (ICRP, 1979; 1980; 1984).
- In 2000, the UK (mandatorily) introduced new regulations that implemented the 1996 Euratom Directive:
 - In compliance with the Euratom Directive, the 2000 UK regulations required all ADSs to apply ICRP's basic 1990 Recommendations (Publication 60; ICRP, 1991) for calculating doses together with Publication 68's (ICRP, 1994) physiologically-based **biokinetic** models.

What Did IMBA Achieve?

- UK ADSs were able to substitute the “computational” cores of their existing “dose assessment systems” with **compatible** “modules” that **performed the necessary new calculations**:
 - E.g., BNFL already had a sophisticated “user-interface” system that enabled relatively unskilled operators to perform routine dose assessments – using input “bioassay” data – according to ICRP 26/30 “rules” and models.
 - Replacement of the “core” ICRP 26/30 computational models with the new “IMBA” modules provided “seamless” transition to compliance with the new (2000) UK regulations.
- Common adoption of the **IMBA** modules by **ALL UK ADSs** introduced **UNIFORMITY** in dose assessments throughout the UK – with **LOW** system programming overhead for the UK ADSs.

What Is Internal Dose Assessment?




European Radiation Dosimetry Group

EURADOS →

1. Introduction

Types of internal dose assessment



What Does It Involve?



European Radiation Dosimetry Group

EURADOS →

1. Introduction


Example: Respiratory tract model (structure)

Extrathoracic airways

Bronchial

Bronchiolar

Alveolar interstitial



5 main regions

ET₁

ET₂

BB

bb

AI

How Is the Respiratory Tract “Modeled”?

– The ICRP 66 (1994) Human Respiratory Tract Model (HRTM)



European Radiation Dosimetry Group


EURADOS →

1. Introduction

Example: Respiratory tract model (biokinetics)

Particle transport

Absorption



How Are HRTM Tissue Doses Calculated?



European Radiation Dosimetry Group


EURADOS

1. Introduction

Example: Respiratory tract model (dosimetry)

Source regions


regions (5)	sources (17)
ET ₁	surf
ET ₂	surf, seq, bnd
BB	fast, slow, seq, bnd, AI
bb	fast, slow, seq, bnd, AI
AI	all cells
Lymph	LN _{ET} LN _{TH}




Target regions

regions (5)	targets (17)
ET ₁	basal
ET ₂	basal
BB	basal + secretory
bb	basal
AI	all cells
Lymph	all cells


BB



bb



How Do the IMBA Modules Put All These Calculations Together?



Six independent modules – integrated via standard ASCII
 INPUT/OUTPUT data sets – can be run in any order to perform **ALL**
 required dose calculations:

Prospective – dose per unit intake
 Retrospective – dose from bioassay measurements

What Are the Advantages of the Modular Design Ethos?

- Symbiotic relationship with quality assurance – the same (generic) modules act for ALL elements (and radiouclides).
- Readily enables each component of the (complex) dose calculation to be tested (to whatever precision is necessary to identify “anomalies” – not just one final dose coefficient).
- Applies previously quality assured code, e.g., LUDEP (in IMBA_DEP) – LUDEP was used to generate the reference regional deposition values for the HRTM (ICRP 66).
- The original IMBA modules were developed independently by separate teams (using different mathematical and coding approaches) – and results were rigorously compared with the output of NRPB’s PLEIADES code (one of the codes used to generate ICRP reference dose coefficients).
- The same modules can be run in different orders – for different types of calculation (prospective or retrospective).
- The modules can readily be controlled by an external code, e.g., they can be incorporated into existing (or specially developed) software by treating them as subroutines.

The First “User Friendly Interfaces” for IMBA: *IMBA-CALC* and *IMBA-URAN*

The first stand alone implementations of the IMBA modules were IMBA-CALC and IMBA-URAN. Both programs were designed to be extremely simple to use as opposed to utilising the full capabilities of the IMBA modules. IMBA-CALC estimates intakes and calculates internal doses for a limited number of radionuclides at the click of a button. IMBA-URAN was designed specifically for uranium dosimetry.

Figure 1

Main screen of IMBA-CALC. This was one of the first programs to utilise the IMBA modules.

Both programs show how the interfaces to the modules can be customised to meet the precise requirements of the end user.

Extension of the IMBA Modules to Accommodate Different Dosimetry Rules and Regulatory Practices: The IMBA Expert™ Concept


- Develop an **intuitive** (i.e., user friendly) MS Windows®-based **interface** that can be **customized** for any dose assessment application or **methodology**.
- Extend **core** IMBA modules to introduce new computational capabilities, e.g.:
 - **Substitute the dosimetry rules mandated by 10CFR835** for the ICRP Publication 60/68 rules.
 - Provide simultaneous statistical analyses (fitting) of multiple bioassay data and different types of data (bioassay quantities).

“Exporting” the Concept of National Uniformity in Internal Dose Assessments to the U.S.!

- In 2000, Drs. Birchall and James (representing ACJ & Associates, Inc., Richland, WA) “floated” the possibility of applying NRPB’s “IMBA” concept to provide a common “tool” to USDOE’s site dosimetry services – which would:
 - Give USDOE sites the capability of applying “uniformly” the current (ICRP 68) biokinetic models and the ICRP 66 HRTM – **whilst preserving their compliance with 10CFR835.**
- DOE’s Office of Worker Protection Policy and Programs (EH-32) recognized the benefits of such an approach:
 - EH-32 encouraged Birchall and James to seek the funding for the necessary development effort directly from the major individual DOE sites (the “Users”) – **whilst also establishing the “special requirements” (product specifications) for each site.**

The Outcome: IMBA Expert™ USDOE-Edition

Following visits in October 2000 to nine major USDOE nuclear sites, an ambitious project to develop a single software package to satisfy all of their requirements for internal dosimetry was established.



IMBA Expert™ USDOE-Edition was developed in two phases – under an umbrella contract between USDOE and ACJ & Associates, Inc. (ACJ).

ACJ sub-contracted the UK NRPB (the IPR owner of IMBA) to co-develop IMBA Expert™ USDOE-Edition (and write the code). ACJ and NRPB shared the resulting IPR.

The final “product” (Phase II) was delivered in 2004 – and subsequently “licensed” by 26 DOE sites.

Features of *IMBA Expert™ USDOE-Edition*

Different Routes of Intake:

- Inhalation (Aerosols and Vapours)
- Ingestion
- Injection
- Wound

Built-in Databases of Parameter Values:

- All ICRP defaults
- Bioassay functions
- Biokinetic models
- Nuclear decay data

Different Modes of Intake:

- Acute
- Chronic
- 10 intake regimes simultaneously
- Mixed intakes e.g. inhalation and ingestion

Bioassay Calculations:

- Calculate bioassay quantities (urine, faeces, whole body, lung, organ retentions)
- Estimate up to 10 intakes simultaneously
- Deal with data recorded at less than limit of detection using the maximum likelihood method
- Deal with different errors and error assumptions on each data point
- Simultaneously fit to more than one bioassay type (e.g. urine and lung data)

Simple and Easy to use!

Ability to Change Parameters:

- Aerosol (size, density etc)
- Particle transport
- Absorption rates
- Retention/excretion functions
- Wound model parameters
- GI-tract model **parameters**, f_1

Other Features

- Produce graphical output
- Download to spreadsheets
- Enter Time or Dates
- Generate reports
- Access help files and technical documentation

Dose Calculations:

- Equivalent Dose to all organs
- Effective Dose
- **CFR**/ICRP/User defined tissue weighting factors and remainder rules
- Up to 30 associated radionuclides

“User Interface” of *IMBA Expert™ USDOE-Edition*

Main Screen

File Edit Parameters Calculations Tools Advanced Help

Open Save New Quick Save Load Load Report Help

Sep 2002

Ver 2.0 No file opened

IMBA Expert Oxford Conference Edition *nrpb*

Intake Scenario

Intake Regimes

Clear All Intake Regimes Enter Number of Intake Regimes (1-10) 1

IR 1

Route: ☒ Inhalation ☐ Ingestion ☐ Injection ☐ Wound ☐ Ventr

Mode: ☒ Acute ☐ Chronic

Start Time(d): 0

Units

Specify Time As: ☐ Date ☒ Time (d) times

Intake: ☒ Bq ☐ dpm ☐ pCi ☐ nCi

Dose: ☒ Sv ☐ Rem ☐ mSv ☐ mRem

Intake (IR 1)

1 Bq

Indicator Nuclide

Select Radionuclide Pu-239

Number of Associated Radionuclides: 0

Half Life: 876000 d

Associated Radionuclides

None Selected

Model Parameters

These Model Parameters Apply to All IRs

Respiratory Tract

Deposition Ventr Wound Bioassay

Particle Transport Absorption GI-Tract Biokinetics

Calculations

Bioassay Calculations

Dose Calculations

All IRs Absorption: Type M Part Trans: ICRP Defaults GI-Tract: ICRP Defaults IR=0.0005 Biokinetics: ICRP Pu Model Deposition: ICRP Defaults AMAD: 5 µm Wound: Not Specified

Figure 2

Main screen of *IMBA Expert™*. Radionuclides and intake regime(s) are specified in the upper part of the screen, while the model parameters and types of calculation are specified in the lower part.

“Bioassay Calculations” in *IMBA Expert™ USDOE-Edition*




Figure 3

Bioassay screen of IMBA Expert™. The software can perform a variety of calculations including calculating an intake from several bioassay data sets simultaneously.

Special Feature of *IMBA Expert*[™] *USDOE-Edition*: Ability to “Select” Tissue Weighting Factors

Table A.3.2. Comparison of “Default” tissue weighting factors implemented in *IMBA Expert*[™] *OCAS/ORAU-Edition*.

Organ or tissue (T)	ICRP60/68 Default	10-CFR-835 Default	ICRP26/30 Default
Gonads ¹	0.20	0.25	0.25
Bone marrow (red)	0.12	0.12	0.12
Colon ²	0.12	-	-
Lung	0.12	0.12	0.12
Stomach wall	0.12	-	-
Urinary bladder	0.05	-	-
Breast	0.05	0.15	0.15
Liver	0.05	-	-
Esophagus	0.05	-	-
Thyroid	0.05	0.03	0.03
Skin	0.01	-	-
Bone surface (endosteal)	0.01	0.03	0.03
Remainder	0.05	0.3	0.3

¹The dose to the gonads is calculated as the higher of those calculated for the testes and ovaries (in the hermaphrodite worker considered by ICRP).

²The dose to the colon is calculated as the mass-weighted-average of that to the walls of the upper large intestine (ULI) and lower large intestine (LLI).

Ability to “Select” Remainder Tissue and “Splitting” Rules

Table A.3.3 Comparison of “Default” remainder tissues implemented in [IMBA Expert™](#) OCAS/ORAU-Edition.

Organ or tissue (T)	ICRP60/68	10 CFR 835	ICRP26/30
Muscle	•	•	•
Brain ¹	•	(•)	
Small intestine wall	•	•	•
Kidneys	•	•	•
Pancreas	•	•	•
Spleen	•	•	•
Thymus	•	•	•
Uterus	•	•	•
Adrenals	•	•	•
Extrathoracic airways ¹	•	(•)	
Gall bladder ¹		(•)	
Heart wall ¹		(•)	
Urinary bladder ²		•	•
Esophagus wall ^{1,2}		•	
Liver ²		•	•
Stomach wall ²		•	•
Upper large intestine wall ³		•	•
Lower large intestine wall ³		•	•

¹These organs were not considered explicitly in the ICRP26/30 recommendations. However, with the endorsement of OCAS/EH-31, [IMBA Expert™](#) OCAS/ORAU-Edition includes them in the default list of “candidate” remainder tissues.

²These organs are given specific tissue weighting factors in ICRP60/68.

³These organs are included in the Colon, which is given a specific weighting factor in ICRP60/68.

DOE Gap Analysis Recommending “Adoption”

DOE/EH-0711

Gap Analysis for IMBA and DOE Safety Software Central Registry Recommendation



Final

**U.S. Department of Energy
Office of Environment, Safety and Health
1000 Independence Avenue, S.W.
Washington, D.C. 20585-2040**






Parallel Developments to *IMBA Expert*™ *USDOE-Edition*

- *IMBA Expert*™ *NIOSH-Edition* – custom-developed for CDC/NIOSH/OCAS as a ‘bread-board’ calculator for them to carry out preliminary assessments in support of the 2000 Energy Employees Occupational Injury Compensation Program Act (EEOICPA). Delivered in 2002.
- *IMBA Expert*™ *CANDU-Edition* – custom-developed for the (Canadian) CANDU Owners Group, Toronto, Ontario. Delivered in 2004.
- *IMBA Expert*™ *UK-Edition* – custom-developed for UK ADs. Delivered in 2004.
- *IMBA Expert*™ *OCAS/ORAU-Edition* – custom-developed for Oak Ridge Associated Universities (ORAU) to enable HP dose-assessors to perform the standardized calculations of annual tissue doses required for substitution in the *Interactive RadioEpidemiology Program (IREP)* for cancer causation probability determination. Delivered in several phases (through 2005).

IMBA Expert™ OCAS/ORAU-Edition

IMBA Expert™ OCAS-Edition

- Just three, easy-to-navigate, tightly-integrated work screens!



“Internationalizing” the IMBA Concept: The UK HPA-RPD’s *IMBA Professional Plus (IPP)*

IMPA Professional Plus is the successor of the IMBA Professional and IMBA Expert™ series. It is more flexible, more powerful and 6 - 10 times faster. The central concept behind the software is that the nucleus of the program (called the Base Unit) can be installed and run as a separate entity, enabling basic internal dosimetry calculations to be performed. More powerful capabilities (called Add-ons) can be added to the Base Unit as required. Each Add-On can be installed independently, and increases the functionality of the software. The users can thus build up the software to meet their precise requirements.




IPP Provides Bioassay Analysis Software in a Range of Standard (off-the-Shelf) “Packages”


Add-On	Description of Add-On
1	Enables up to 10 independent intake regimes to be specified and used together in calculations
2	Allows different types of measurement data to be used simultaneously in the assessment of intake(s)
3	Enables up to 30 associated radionuclides to be specified and used in dose calculations
4	Used to enable different isotopic mixtures of uranium (eg, enriched, natural) to be specified and used in calculations
5	Implements a generic wound model, enabling intakes via wound to be dealt with
6	In cases where the data is normally distributed, and there is only 1 intake, this Add-On will automatically calculate the error on the estimate of intake
7	Incorporates a Bayesian fitting methodology allowing the user to investigate the effects of different 'prior' knowledge on intake estimates, combine bioassay data with PAS data, and obtain uncertainties in estimates of intakes
8	A tool used to analyse measurements of tritium in urine from a routine tritium monitoring procedure
9	Specifically designed for calculating doses to a specified organ in each calendar year. Used for input into compensation type calculations
10	Enables the ingrowth of ^{241}Am from ^{241}Pu to be automatically allowed for in calculations (Chronic intakes cannot be used with this Add-On)
11	A statistics package giving a quantitative judgement as to the goodness of fit of the assumed models to the measurement data

IPP Maintains the “Look and Feel” of *IMBA Expert*™: But with Significantly Enhanced Features and Capabilities

Main screen.
Upper screen defines intake scenario, while parameters can be changed in the bottom half.




A simultaneous fit to the bioassay data in the IDEAS International Intercomparison exercise (case 6).



Radionuclides are selected from a periodic table from which further decay information may be viewed.


ALL versions of IMBA are “backwards compatible” – and share a standard ascii data file format (“*.ix” case data).

IPP Has Been Adopted Very Widely!



So how can an “IMBA-derived” code system help the U.S. Nuclear Regulatory Commission?

The Future of “IMBA” – Ongoing Research & Development



The U.S. Transuranium & Uranium Registries is actively collaborating with Drs. Birchall and Puncher to **TEST** novel (IMBA-based) analytical capabilities (and methods) with **Registries case studies**.

Implementation (and Testing) of Proposed New ICRP Models

Main Screen

File Edit Parameters Calculations Tools Advanced Help

Open Save New Quick Save ICRP DEFS LFR DEFS REP Help IDEAS

Ver 4.1 Add-Ons: 12 C:\JABASoft\IMBAEXUS\USERDATA\Leggett_Pu_Future_ICRP.ix File appended

Feb 10

Current ICRP Future ICRP

Health Protection Agency

IMBA Professional Plus Academic Edition

Intake Scenario

Intake Regimes

Clear All Intake Regimes Enter Number of Intake Regimes (1-10) 1

IR 1

Route: ☒ Inhalation ☐ Ingestion ☐ Injection ☐ Wound ☐ Vapor

Mode: ☒ Acute ☐ Chronic

Start Time (d) 0

Units

Specify Time As: ☐ Date ☒ Time (d) since 1/1/1980

Intake: ☒ Bq ☐ dpm ☐ pCi ☐ mg

Dose: ☒ Sv ☐ rem ☐ mSv ☐ mrem

Intake (IR 1)

0 Bq

Indicator Nuclide

Select Radionuclide **Pu(Leg)-239**

Number of Associated Radionuclides: 0

Half Life: 8.784E+06 d

Associated Radionuclides

None Selected

Model Parameters

These Model Parameters Apply to All IRs

Respiratory Tract: Deposition Vapor Wound Bioassay

Particle Transport Absorption GI-Tract Biokinetics

Close


Calculations

Bioassay Calculations


Dose Calculations

All IRs Absorption: Not Specified Part Tran: Not Specified GI-Tract: Not Specified f1= Biokinetics: Not Specified Deposition: Not Specified AMAD: 0 µm Wound: Not Specified

Leggett et al. (2005) – Revised (Improved?) Pu Biokinetics




New Capability: “Build Your Own” Biokinetic Model in IPP!



Recycling model now solved “live” – does not require “pre-cooked” equivalent set of exponential terms (non-recycling approximation)

“IMBA” Computational Module Options Available in IPP Vers. 4.1.2 (64-bit Compatible)



Can Implement – and Vary Parameter Values in – the ICRP 100 Human Alimentary Tract (HAT) Model

HAT model (simplified)

Rate constants (per day) for particulate material

Oral to Desophagus Fast	7200
Oral to Desophagus Slow	7200
Desophagus Fast	12343
Desophagus Slow	2160
Stomach (St)	20.57
Small Intestine (SI)	6
Right Colon (RC)	2
Left Colon (LC)	2
Recto-sigmoid	2

Clear

f_A

Select


User Defined

LOAD ICRP DEFAULTS


ICRP Defaults

OK Cancel

New “IMBA Dosimetry” Modules for “Future” ICRP Dose Calculations



Can Select Any “Compartment” of a Biokinetic Model as a New “Bioassay Quantity”



New Radon (and Thoron) Progeny Dosimetry “Tool”

Radon Tool

File Defaults

Setup

Setup IMBA for Rn

Defaults

Use All default s

Exposure parameters

Gas PAEC

Exposure 1 WLM

☒ calculate

WL h

Units

☒ WLM

☐ J.h/cu.m

Equilibrium factor (F)

0.6 Use defaults ☒

Net Breathing rate

1.4 cu.m/h Use default ☒

Calc breathing rate from physical activities ☐

Edit physical activities

Physical Parameters

Unattached Nucleation Attached Course

Fraction of PAE

0.01 % Use defaults ☒

Aerosol size

Edit Use defaults ☒

Absorption

Edit Use defaults ☒

Ok Cancel

Radon (and Thoron) Progeny Dose Calculations

Main Screen

File Edit Parameters Calculations Tools Advanced Help

Open Save New Quick Save ICRP DEFS Load CFR DEFS Load REP Report ? Help IDEAS

Ver 4.1 Add-Ons: 12 No file opened No file appended Feb 10

Current ICRP Future ICRP

Health Protection Agency

IMBA Professional Plus Academic Edition

Intake Scenario

Intake Regimes

Clear All Intake Regimes Enter Number of Intake Regimes (1-10) 4

IR 1 IR 2 IR 3 IR 4

Route: ☒ Inhalation ☐ Ingestion ☐ Injection ☐ Wound ☐ Vapor

Mode: ☒ Acute ☐ Chronic

Start Time (d) 0

Units

Specify Time As: ☐ Date ☒ Time (d) since 1/1/1980

Intake: ☒ Bq ☐ dpm ☐ pCi ☐ mg

Dose: ☐ Sv ☐ rem ☒ mSv ☐ mrem

Intake (IR 1)

11818.21915851 Bq

Indicator Nuclide

Select Radionuclide **Po-218**

Number of Associated Radionuclides: 2

Half Life: 2.118E-03 d

Associated Radionuclides

Pb-214 Bi-214

Select Radionuclide Abundance 79.527957 %

Delete Radionuclide Half Life: 1.861E-02 d

Model Parameters

IR1 IR2 IR3 IR4

Respiratory Tract

Deposition Vapor Wound Bioassay

Particle Transport Absorption GI-Tract Biokinetics

Close


Calculations

Bioassay Calculations


Dose Calculations

IR 1 Absorption: Radon Part Tran: ICRP Defaults GI-Tract: ICRP Defaults f1=0.1 Biokinetics: ICRP Po Model Deposition: Radon AMTD: 0.0008 µm Wound: Not Specified

Proposed Improvement of HRTM



ICRP Publication 66 (1994)




Gregoratto et al. (in press)




3. Fitting parameters

Overview



Internal Dose Assessment by “Rule Book” Can Get Very Complicated!!



Bayesian Analysis Goes Directly from Uncertainties in Bioassay Data to Uncertainties in Doses




European Radiation Dosimetry Group

EURADOS →

4. Uncertainties

Overview of Bayesian calculation



Example from USTUR Case Study – “In Vivo” Bioassay Data




European Radiation Dosimetry Group

EURADOS →


4. Uncertainties

Example: intake of ^{241}Am aerosol

Lung dose (mGy)



Intake (Bq)



Simultaneous Evaluation of Uncertainties in HRTM Model Parameters




European Radiation Dosimetry Group

EURADOS →


4. Uncertainties

Example: intake of ^{241}Am aerosol

Particle transport K_{PT}




Rapid rate s_r




Case 0202 – Bayesian Posterior Distribution of Intake – Pu Fire

Posterior Probability Distribution of Intake




Case 0202 – Bayesian Posterior Distribution of “Effective” Dose to Lung, $H_E(\text{lung})$



Posterior Probability Distribution of Dose to Lung



Case 0202 – Bayesian Posterior Distribution of Slow Absorption Rate, s_s



Case 0202 – Predicted Annual Dose Rates (Optimized Gregoratto HRTM)



Comparison of Bronchial Target Cell Dose

Bronchial Target Cells

In this case (Pu fire incident), the OHRTM and OGPT models give significantly different estimates of committed dose to bronchial secretory cells (but not basal cells):

Secretory cells


- OHRTM; 7.71 Sv (GSD = 1.33)
- OGPT; 0.273 Sv (GSD = 1.28).

Basal cells

- OHRTM; 0.494 Sv (GSD = 1.32)
- OGPT; 0.398 Sv (GSD = 1.28).




The USTUR Measures α -Dose Rates to Tissues DIRECTLY – From Radiochemical Analyses of Autopsy Samples



Including DIRECT Measurement of Terminal α -Dose Rate to Thoracic (and Axillary) Lymph Nodes

Terminal Dose Rate to Thoracic Lymph Nodes (LNTH) - All Causes of Death
[205 of 331 USTUR Cases]



ICRP Publication 103 Has Changed the Treatment of Lymph Nodes – and Remainder Tissues!!

ICRP Publication 103

Table 3. Recommended tissue weighting factors.

Tissue	w_T	Σw_T
Bone-marrow (red), Colon, Lung, Stomach, Breast, Remainder tissues*	0.12	0.72
Gonads	0.08	0.08
Bladder, Oesophagus, Liver, Thyroid	0.04	0.16
Bone surface, Brain, Salivary glands, Skin	0.01	0.04
	Total	1.00

* Remainder tissues: Adrenals, Extrathoracic (ET) region, Gall bladder, Heart, Kidneys, **Lymphatic nodes**, Muscle, Oral mucosa, Pancreas, Prostate (male), Small intestine, Spleen, Thymus, Uterus/cervix (female).

Some Potential Issues with New ICRP 103 “Dosimetry”

- Not stated whether Thoracic Lymph Nodes (LNTH) are included in the “lymph node dose average” – or how to calculate axillary lymph node dose (for a “wound” intake).
- If LNTH are included, their w_T value would increase by an order of magnitude – from 0.001 (ICRP 66) to about 0.01 (one-fourteenth of the 0.12 “remainder” value).
- At least for the actinides, the radionuclide concentrations (tissue doses) for the Breast, Brain, Salivary glands, Skin, Adrenals, Gall bladder, Heart, Pancreas, Prostate, Spleen, Thymus, Uterix/cervix are not “modeled” – and autopsy data indicates substantial differences from Massive Soft Tissue (MST).

Concluding Remarks (Personal Observations)

- As found by many Approved Dosimetry Services (including the USDOE), a “unified” and pre-quality assured approach to formalizing internal dose assessment (such as the “modular” approach embodied in IMBA-based codes) is valuable in “seamlessly” implementing significant changes in regulatory practices.
- The developers of IMBA (and the related WeLMoS methodology and “interface”) have demonstrated the technical capability to apply these codes flexibly, reliably, and remarkably quickly to help both “Users” and regulators.
- I have tried to illustrate the ‘holistic’ scope and power of this approach in meeting anticipated regulatory needs – and also in stimulating (and facilitating) fundamental research on the quantification (and reduction) of uncertainty in internal dose assessment.

Disclaimer: “This presentation was prepared as an account of work partly sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of author expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof” – or the views and policies of the UK Health Protection Agency.

Thank you for your attention!

www.ustur.wsu.edu

